Jefferies Cuts Price target on Auris Medical Holding (EARS) Following 4Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Francisco Partners to acquire Weave Communications for $650M
Auris Medical Holding (EARS) Reports Q4 Loss of CHF0.16/Share
March 14, 2016 6:36 AM EDTAuris Medical Holding (NASDAQ: EARS) reported Q4 EPS of (CHF0.16), versus (CHF0.17) reported last year.
"We achieved significant progress with our development programs in 2015, bringing us closer to the completion of the pivotal AM-101 tinnitus trials and advancing the late-stage AM-111 hearing loss program," commented Thomas Meyer, Auris Medical's founder, Chairman and Chief Executive Officer. "We look forward to the upcoming results of our Phase 3 AM-101 program, initiating the second of our Phase 3 AM-111 trials and attaining further progress towards our ultimate goal of providing effective and safe inner ear therapeutics for... More
Trading Radar for 3/14: 3D Systems (DDD), MannKind (MNKD), A.M. Castle (CAS), Partner Communications (PTNR) Report
March 11, 2016 3:30 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Earnings:
3D Systems (NYSE: DDD) - consensus EPS $0.03
A.M. Castle & Co. (NYSE: CAS) - no Street consensus
Auris Medical Holding (Nasdaq: EARS) - consensus loss $0.28
Biospecifics Technologies (Nasdaq:... More
